Clinical trials: Hereditary Hemochromatosis
Hemochromatosis, Cerebrovascular Accident
Stroke With Transfusions Changing to Hydroxyurea
The purpose of this study is to compare standard therapy (transfusions and chelation) with alternative therapy (hydroxyurea and phlebotomy) for the prevention of secondary stroke and management of iron overload in children with…
- Conditions
- Hemochromatosis, Cerebrovascular Accident, Anemia, Sickle Cell, Hematologic Diseases
- Trial name
- NCT00122980
- Testing
- Red Cell Transfusions, Iron Chelation, Hydroxyurea
- Where
- 28 sites in United States
- Volunteers
- 134 people
- Sponsor
- St. Jude Children's Research Hospital
Beta-thalassemia Major, Sickle Cell Disease
Study Of Efficacy,Safety of Combined Deferasirox and Deferiprone Versus Combined Deferiprone and Desferal In Conditions of Iron Overload
Interventional Allocation: Randomized Endpoint Classification: Safety/Efficacy Study of combined chelation therapy Masking: Open Label Primary Purpose: Treatment of transfusional iron overload Primary Outcome Measures: The…
- Conditions
- Beta-thalassemia Major, Sickle Cell Disease, Iron Hemosiderosis
- Trial name
- NCT01511848
- Testing
- DFP (ferriprox) and deferasirox (ICL 670), DFP, DFO
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Ain Shams University
Hereditary Hemochromatosis
A Study to Evaluate BBI-001 in Hereditary Haemochromatosis (HH) Patients and Iron Deficient Volunteers
This is a first in human, double-blind, randomized, placebo-controlled, two-arm crossover study evaluating the safety, tolerability and PD of ascending dose levels of BBI-001 after: a single administration in iron deficient male…
- Trial name
- NCT05238207
- Testing
- BBI-001, Original Fibre Metamucil
- Where
- Australia
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Bond Biosciences
Hemochromatosis Type 1
Impact of Bloodletting on Iron Metabolism in Type 1 Hemochromatosis
Hemochromatosis type 1 is one of the most frequent genetic disease since the genetic predisposition (homozygosity for the C282Y mutation of the HFE gene) is encountered in about 3/1000 white subjects (5/1000 in Brittany, France).
- Trial name
- SAIFER (NCT01810965)
- Testing
- First evaluation phase : no intervention / Second evaluation phase: bloodletting of 7 ml/kg (with a maximum of 500ml)
- Where
- France
- Volunteers
- 6 people
- Sponsor
- Rennes University Hospital
Anemia (Iron-Loading), Beta-Thalassemia
Evaluation of Subcutaneous Desferrioxamine as Treatment for Transfusional Hemochromatosis
To determine whether deferoxamine prevented the complications of transfusional iron overload.
- Conditions
- Anemia (Iron-Loading), Beta-Thalassemia, Hematologic Diseases, Hemoglobinopathies
- Trial name
- NCT00000595
- Testing
- deferoxamine
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Genetic Hemochromatosis
Respiratory Variations For Assessing Blood Withdrawal
OBJECTIVES: To investigate whether respiratory variations of the inferior vena cava (ΔIVC) and internal jugular vein (ΔIJV) diameters during standardized breathing (ΔIVCST and ΔIJVST) increase after a therapeutic bleeding in…
- Trial name
- ReVAs (NCT03066414)
- Testing
- echography
- Where
- France
- Volunteers
- 27 people
- Sponsor
- University Hospital, Lille
Sickle Cell Disease
Liver Fibrosis in Sickle Cell Disease
Patients with sickle cell disease many have a number of systemic complications, including liver problems. Some of these liver problems lead to liver fibrosis/cirrhosis, secondary to chronic blood transfusions.
- Trial name
- NCT02007746
- Testing
- Liver transient elastography (Fibroscan), Ferriscan, Liver biopsy in iron overloaded subjects.
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- University of Miami
Hereditary Hemochromatosis
Study to Evaluate the Efficacy and Safety of Deferasirox Film-coated Tablet Versus Phlebotomy in Patients With Hereditary Hemochromatosis (HH)
The purpose of this study was to evaluate the efficacy and safety of deferasirox film coated tablet (FCT) versus phlebotomy for the management of iron overload in adults with Hereditary Hemochromatosis (HH) at risk of…
- Trial name
- NCT03203850
- Testing
- Deferasirox FCT, Phlebotomy
- Where
- 11 sites in Belgium, France and 5 more
- Volunteers
- 45 people
- Sponsor
- Novartis Pharmaceuticals
Homeostatic Iron Regulator Gene-related Hereditary Hemochromatosis
Efficacy and Safety of Vamifeport in Adult Participants With Homeostatic Iron Regulator Gene (HFE)-Related Hereditary Hemochromatosis
This is a phase 2, multicenter, randomized, placebo-controlled, double-blind, parallel-group, proof-of-concept study to assess vamifeport in adult participants with homeostatic iron regulator gene-related hereditary…
- Trial name
- NCT07332091
- Testing
- Vamifeport
- Where
- 100 sites in United States, Australia and 16 more
- Volunteers
- 84 people
- Sponsor
- CSL Behring
Iron Metabolism Disorders, Iron Overload
Inhibiting Dietary Iron Absorption in Subjects With Hereditary Hemochromatosis by a Natural Polyphenol Supplement
Polyphenolic compounds are very strong Inhibitors of non-heme iron absorption, as they form insoluble complexes with ferrous iron.
- Conditions
- Iron Metabolism Disorders, Iron Overload, Polyphenols
- Trial name
- NCT03990181
- Testing
- meal matrix & NPPS, meal matrix & CS, no-matrix & NPPS
- Where
- 2 sites in Portugal, Switzerland
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Swiss Federal Institute of Technology
Hemochromatosis
Proton Pump Inhibitors in the Prevention of Iron Reaccumulation in Patient With Hereditary Hemochromatosis
Hereditary Hemochromatosis (HH) is a genetic disorder of iron metabolism, resulting in excessive iron overload causing damage of different important organs like heart, liver, pancreas and joints.
- Trial name
- He-ppi (NCT01524757)
- Testing
- Pantoprazole
- Where
- 3 sites in Belgium, Netherlands
- Volunteers
- 48 people
- Sponsor
- Maastricht University Medical Center
Transfusional Iron Overload
A Protocol to Allow Treatment With ICL670 for Patients With or at Risk of Life-threatening Complications of Transfusional Iron Overload Who Are Unable to Tolerate Other Iron Chelators Because of Documented Severe Toxicity
The purpose of this open-label, non-comparative, multi-center protocol was to further evaluate safety and to provide treatment with ICL670 to patients who had or were at risk of life threatening complications due to transfusional…
- Trial name
- NCT01044186
- Testing
- ICL670
- Where
- 18 sites in United States, Greece and 1 more
- Volunteers
- 30 people
- Sponsor
- Novartis Pharmaceuticals
Hereditary Hemochromatosis
Clinical Management of Hereditary Hemochromatosis: Phlebotomy vs. Erythrocytoapheresis
The purpose of study is to determine the best and durable choice of treatment between phlebotomy and eritrocytoapheresis in the medium- and long-term clinical management of HH
- Trial name
- NCT00440986
- Testing
- Eritrocytoapheresis
- Where
- Italy
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- San Filippo Neri General Hospital
Refractory Hemochromatosis Rheumatism
Treatment of Refractory Hemochromatosis Rheumatism by Anakinra: a Preliminary Phase II Study
Treatment of refractory hemochromatosis rheumatism by Anakinra. Prospective, multicenter, non-randomised, single-arm, open-label, phase II trial.
- Trial name
- THERA (NCT02263638)
- Testing
- Anakinra
- Where
- 3 sites in France
- Volunteers
- 17 people
- Sponsor
- Rennes University Hospital
Liver Diseases, Primary Biliary Cirrhosis
Repeatability and Reproducibility of Multiparametric MRI
This study aims to prospectively assess the repeatability and reproducibility of iron-corrected T1 (cT1), T2*, and hepatic proton density fat fraction (PDFF) quantification with multiparametric MRI using the LiverMultiScan™ (LMS…
- Conditions
- Liver Diseases, Primary Biliary Cirrhosis, Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis
- Trial name
- NCT03743272
- Testing
- LiverMultiScan
- Where
- 4 sites in Netherlands, United Kingdom
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Perspectum
Hereditary Haemochromatosis
Mi-iron - Moderately Increased Iron - is Reducing Iron Overload Necessary?
Haemochromatosis is a preventable genetic iron overload disorder. Untreated, it can shorten life due mainly to liver cirrhosis and cancer. It can be prevented by blood donation to maintain normal iron levels.
- Trial name
- Mi-iron (NCT01631708)
- Testing
- Erythrocytapheresis, Plasmapheresis
- Where
- 3 sites in Australia
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Murdoch Childrens Research Institute
Hemochromatosis, Iron Overload
MRI QSM Imaging for Iron Overload
The overall goal of this project is to develop and validate a novel technique for Magnetic Resonance Imaging (MRI)-based Quantitative Susceptibility Mapping (QSM) of the abdomen, for non-invasive assessment of liver iron…
- Trial name
- NCT04631718
- Testing
- Magnetic Resonance Imaging (MRI)-based Quantitative Susceptibility Mapping (QSM)
- Where
- 2 sites in United States
- Volunteers
- 63 people
- Sponsor
- University of Wisconsin, Madison
Down Syndrome
Infectious and Non-infectious Lower Respiratory Diseases in Children With Down Syndrome Followed in Pediatric Pulmonology Consultations in Ile-de-France
The purpose of this study is to describe infectious and non-infectious lower respiratory tract diseases in children with Down syndrome followed in pediatric pulmonology consultations in Ile de France.
- Trial name
- ARBT21 (NCT06336577)
- Testing
- lower respiratory tract disease
- Where
- France
- Volunteers
- 108 people
- Sponsor
- Centre Hospitalier Sud Francilien
Porphyria Cutanea Tarda
Risk Factors of Porphyria Cutanea Tarda (PCT)
Comparison of patients with documented PCT and HCV infection, documented PCT without HCV, HCV infection without PCT and controls without HCV or PCT.
- Trial name
- NCT00213772
- Volunteers
- 280 people
- Sponsor
- University Hospital, Strasbourg, France
Beta-Thalassemia, Hemosiderosis
A Study of Long-term Treatment With Deferasirox in Patients With Beta-thalassemia and Transfusional Hemosiderosis
Because patients with beta-thalassemia are unable to actively eliminate iron from the body, toxic and eventually lethal levels of iron can accumulate as a result of repeated blood transfusions.
- Trial name
- NCT00171171
- Testing
- deferasirox
- Where
- 5 sites in Egypt, Lebanon and 3 more
- Volunteers
- 252 people
- Sponsor
- Novartis